Refine by
Patient Follow Up Services
6 services found
by:Click Therapeutics, Inc based inNew York, NEW YORK (USA)
Deliver effective treatments to your patients. Our clinically validated software programs are designed to deliver effective treatments to your patients while offering the favorable safety profile inherent to a digital ...
by:Liver Transplant India based inNoida, INDIA
The liver specialist usually suggests this evaluation once he has diagnosed end-stage liver disease. Recipient evaluation is done in three phases and normally takes 5-7 days in ...
Manufactured by:Colibri Heart Valve LLC based inLouisville, COLORADO (USA)
Colibri recently initiated a clinical early feasibility study (EFS) which is an international prospective, non-randomized, single arm, open label, trial to assess early feasibility of the Colibri second-generation 24mm and 27mm percutaneous, ready-for-use, balloon expandable aortic heart valve and delivery system. The company’s second-generation TAVI system includes enhancements to address ...
Manufactured by:Firalis Group based inHuningue, FRANCE
Firalis has extensive experience in data analysis and utilizes innovative techniques to identify novel biomarker candidates for diagnostics, patient stratification and follow-up or treatment response. Our statistical department can support your projects with the analysis and integration of multidimensional data through the lifecycle of your ...
by:Liver Transplant India based inNoida, INDIA
According to international guidelines, any patient suffering from liver cirrhosis who is assessed to have a life expectancy of less than a year should be considered for a transplant. Severity of liver disease is graded from A to C. Usually all Grade C and most grade B patients are candidates for transplant. ...
by:ICON plc based inDublin, IRELAND
ICON's cardiovascular trial experience, supported by a global team of experts. ICON has extensive experience in cardiovascular clinical research trials across the entire drug development spectrum. There is still significant unmet need within select cardiovascular/metabolic (CVM) disorders. Unfortunately, the cost of developing drugs and devices in this area has been rising steadily. ICON, a full ...